Altre lingue Design Therapeutics, Inc.

Azioni

DSGN

US25056L1035

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 02/05/2024			Variaz. 5gg	Var. 1 gen.
3,66 ^USD	+1,10%		-2,66%	+38,11%

20/03	Aggiornamento settoriale: i titoli del settore sanitario calano nel tardo pomeriggio	MT
20/03	Aggiornamento settoriale: titoli del settore sanitario in calo mercoledì pomeriggio	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sector Update: Health Care Stocks Ease Late Afternoon	20/03
Sector Update: Health Care Stocks Down Wednesday Afternoon	20/03
Design Therapeutics Stock Rises as RBC Says Q4 Results, Product Candidate Updates Show Progress	20/03
Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results	19/03
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
North American Morning Briefing : Stock Futures -2-	19/03
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update	12/03
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from NASDAQ Biotechnology Index	15/12
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024	13/11
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	10/10/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	30/09/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	22/09/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	14/09/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	06/09/23
Insider Buy: Design Therapeutics	31/08/23
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN	29/08/23
Design Therapeutics, Inc. Announces Principal Financial Officer Changes	25/08/23
Design Therapeutics, Inc. Announces CEO Changes	25/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Design Therapeutics, Inc.

Azioni

DSGN

US25056L1035

Altre lingue

Filtri